Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MLN0128 alone and with paclitaxel in adults with advanced nonhematologic malignancies; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hematologic Malignancy

Drugs mentioned

• MLN0128 (sapanisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Non-hematologic Malignancy | Phase 1 | Status: COMPLETED | Results posted: 2020-02-28